Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Ramucirumab Plus Fluoropyrimidine/Platinum in Japanese Metastatic Gastric/GEJ Adenocarcinoma
jRCT2080222764Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary safety and tolerability of ramucirumab in combination with fluoropyrimidine/platinum regimens.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222764.